XYLEM
30.8.2022 20:01:39 CEST | Business Wire | Press release
Annabelle M. Rayson from Canada receives the prestigious 2022 Stockholm Junior Water Prize for her research on how to treat and prevent harmful algae blooms. HRH Crown Princess Victoria of Sweden announced the winner during a ceremony at World Water Week in Stockholm.
Harmful algae blooms plague aquatic ecosystems around the world. They impact water quality and ecosystem diversity, cause dead zones, and cost the fishing and tourism industries millions of dollars.
Rayson’s father, a commercial fisherman, could no longer fish in certain areas due to harmful algae blooms, so she undertook research to find a method to treat and prevent them.
Rayson learned the concept of biomanipulation, and which species of zooplankton was best to treat and prevent algae blooms. For this, she was announced as winner of Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.
Speaking on winning the prize, Rayson said: “It’s an absolute honour to be here with so many other brilliant young people, representing all the small-town little girls out there, dreaming of her own microscope and lab coat. Hey girls, we can still make it.”
The Jury noted that “the winning entry has a potential solution for a multi-faceted global problem. It is not just an issue for human health, but it also affects water courses and the species that live within them. Of the challenges we face in terms of public health, many are intimately intertwined with water quality, and the winner – dedicated, passionate and creative – has conducted extensive, bio-inspired research to address this pervasive issue.”
The winner was presented with her prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.
The Diploma of Excellence was awarded to Laura Nedel Drebes and Camily Pereira dos Santos from Brazil, for addressing the issue of period poverty – the inaccessibility to sanitary pads – with their development of sustainable and affordable sanitary pads from industrial by-products.
The People’s Choice Award went to Mishal Faraz from United Arab Emirates, completing the all-female line-up of winners.
The Stockholm Junior Water Prize has been organized every year since 1997 by the Stockholm International Water Institute, SIWI, with Xylem as Founding Partner.
“All Stockholm Junior Water Prize participants show passion and ingenuity that is truly inspiring and an important contribution towards a better future and a more water-wise world. Stockholm Junior Water Prize is a wonderful opportunity to celebrate these contributions,” said Torgny Holmgren, Executive Director at Stockholm International Water Institute.
Patrick Decker, President and CEO of Xylem, added: “On behalf of more than 17,000 Xylem colleagues around the world, I applaud all Stockholm Junior Water Prize 2022 participants, bringing their passion and their innovation to solve the world’s major water challenges. These students inspire us by embodying what’s possible when innovators from around the world come together – with bold ideas and conviction – to solve water.”
For more information: www.siwi.org/prizes
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom